CIBMTR collects comorbidities data based on criteria from the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI), which was developed and validated by investigators at the Fred Hutchinson Cancer Research Center in Seattle, Washington. The HCT-CI was developed to identify comorbidities relevant to transplant and act as a tool for risk assessment before allogeneic hematopoietic stem cell transplantation. While the criteria were originally developed for use in the adult, allogeneic population, there is utility in collecting these data for all transplant populations, and used in conjunction with other relevant risk factors, these data are useful in determining risk for transplant for the purposes of predicting expected outcomes.
What to Report
Report a comorbidity in all the following areas if any of the specified criteria are met.
Comorbidity | Definition and/or criteria | Where to look within the EMR¹ |
---|---|---|
Arrhythmia | Adults and Pediatrics: Any history of (but not limited to) one or more of the following which required antiarrhythmic treatment:
|
|
Cardiac (Cardiovascular disease) | Adults and Pediatrics: The presence of one or more of the following:
|
|
Cerebrovascular disease | Adults and Pediatrics: Any history of one or more of the following:
|
|
Diabetes | Adults and Pediatrics: Current (within 4 weeks prior to HCT / CT) history of diabetes or steroid-induced hyperglycemia requiring insulin or oral hypoglycemics, not controlled by diet alone. |
|
Heart valve disease | Adults and Pediatrics: The presence of one or more of the following, found on the most recent heart evaluation by an echocardiogram:
|
|
Hepatic, mild | Adults and Pediatrics: Any one or more of the following:
|
|
Hepatic, moderate/severe | Adults and Pediatrics: Any one or more of the following:
|
|
Infection | Adults: The presence of one or more of the following requiring therapeutic antimicrobial / antifungal / antiviral treatment starting prior to the preparative regimen / lymphodepleting therapy (or prior to Day 0 if no preparative regimen / lymphodepleting therapy is being given) with a recommendation to continue treatment after Day 0: - Documented infection, - Fever of unknown origin, - Pulmonary nodules suspicious for fungal pneumonia - A positive PPD test requiring prophylaxis against TB - Infection requiring antimicrobial treatment continued after Day 0 Pediatrics: The presence of one or more of the following: - History of invasive fungal infection (refer to Is there a history of invasive fungal infection? manual instructions located under the 2400 Comorbid Conditions section for further clarification) - Infection requiring antimicrobial treatment continued after Day 0 Do not report an infection comorbidity if the infection resolved prior to infusion and there was a recommendation to continue, or the recipient continued medication post-infusion as prophylaxis |
|
Inflammatory bowel disease | Adults and Pediatrics: Any history of:
|
|
Obesity | Adults: Body mass index (BMI) > 35.00 kg/m2 Pediatrics: BMI-for-age ≥ 95% during the pre-infusion work-up period. If only the BMI is known, refer to the following link to determine the BMI-for-age: https://www.cdc.gov/growthcharts/. Evaluation of the obesity comorbidity is based on the most recent measurement of the BMI (or weight and height needed for the calculation of BMI) prior to the start of the preparative regimen / lymphodepleting therapy (or prior to Day 0 if preparative regimen / lymphodepleting therapy was not given). |
|
Peptic ulcer | Adults and Pediatrics: Any history of peptic ulcer (gastric or duodenal) confirmed by endoscopy or radiologic diagnosis and the recipient has or is receiving treatment. |
|
Psychiatric disturbance | Adults and Pediatrics: Any psychiatric illness requiring treatment, including regular counselling / therapy sessions, within four weeks prior to the pre-infusion work-up period. Treatment also includes the recommendation / prescription of medication and / or regular counselling / therapy sessions but the recipient is non-compliant. Examples of psychiatric disturbances include, but are not limited to, depression, anxiety, Attention-Deficit Disorder (ADD), Attention-Deficit Hyperactivity Disorder (ADHD), schizophrenia, or bipolar disorder. Do not report for recipients only receiving treatment (including counselling / therapy sessions) “as needed” or PRN |
|
Pulmonary, moderate | Adults and Pediatrics: Any one or more of the following at the time of pre-infusion evaluation:
|
|
Pulmonary, severe | Adults: Any one or more of the following at the time of pre-infusion evaluation: - Adjusted DLCO ≤ 65% - FEV1 ≤ 65%** - Dyspnea at rest attributed to pulmonary disease and not anemia - Requires intermittent or continuous supplemental oxygen Pediatrics: Any one or more of the following at the time of pre-infusion evaluation: - Adjusted DLCO ≤ 65% - FEV1 ≤ 65%** - Dyspnea at rest attributed to pulmonary disease and not anemia - Requires intermediate or continuous supplemental oxygen - History of mechanical ventilation (refer to Is there a history of mechanical ventilation (excluding COVID-19 (SARS-CoV-2)? manual instructions located under the 2400 Comorbid Conditions section for further clarification)
|
|
Renal, moderate/severe | Adults: Any one or more of the following: - Serum creatinine > 2 mg/dL or 177 µmol/L - On dialysis in pre-infusion evaluation period - Prior renal transplant recipient Pediatrics: Any one or more of the following: - Serum creatinine > 2 mg/dL or 177 µmol/L - eGFR <60 ml>2 (by Bedside Schwartz calculation for <18 years old, ckd-epi calculation for ≥18 old) - On dialysis in pre-infusion evaluation period - Prior renal transplant recipient |
|
Rheumatologic | Adults and Pediatrics: Any history of rheumatologic disease requiring treatment including:
|
|
Prior malignancy | Adults and Pediatrics: Any solid tumor(s),hematologic malignancy(ies), and / or skin malignancy(ies) that have been treated at any time point in the recipient’s past history. Treatment includes surgery and/or resection. A history of any benign tumor(s) should not be reported. If the recipient is receiving an infusion for a disease that transformed from one disease to another (i.e., MDS to AML, CLL to NHL), the original malignancy should not be reported as a comorbidity. Details regarding disease transformation will be captured on the Pre-TED Disease Classification (2402) Form. For more information regarding disease combinations and transformations, refer to the Common Disease Combinations and Common Disease Transformations tables in the Primary Disease for HCT section of the Pre-TED Disease Classification (2402) Form. |
|
1 Examples of where to find source documents within the EMR; however, this will vary from institution to institution. Seek physician clarification on where to find this information, as needed.
(*) ULN refers to upper limit of normal for respective laboratory study
(**) If the PFT lists both a “control” FEV1 and “post-dilator” FEV1, the “control” FEV1 should be used to determine if a pulmonary comorbidity is present.
2 Sorror, M. L. (2013). How I assess comorbidities before hematopoietic cell transplantation. Blood, 121(15), 2854-2863.
Determine relevant comorbidities through careful review of the recipient medical record. Reviewed documentation should include the recipient’s past medical history and objective data from the pre-infusion work-up, including pulmonary function tests, echocardiogram, body weight, and laboratory results. The recipient medication list should be correlated with the past medical history to verify there are not any medications that do not align with the recipient’s medical history; if there were to be medications commonly used for a certain purpose not listed in the medical history, further clarify if a relevant comorbidity is present. However, if the medical record remains ambiguous, after careful review, as to whether a condition meets the criteria for reporting comorbidity, do not report.
Report all comorbidities meeting criteria at time of pre-infusion evaluation. This may include comorbidities secondary to the primary infusion disease or conditions resulting from prior therapy and persisting or meeting criteria for reporting at the time of infusion.
For instances in which the pulmonary function testing report does not correct diffusing capacity of carbon monoxide for hemoglobin, use the Dinakara equation to correct.
What not to report
The following conditions are not relevant transplant outcomes or risk, and should not be reported under the comorbidities section.
|
|
|
Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.
Date | Manual Section | Add/Remove/Modify | Description |
---|---|---|---|
12/20/2023 | Appendix J: Reporting Comorbidities | Add | Prior Skin Malignancy blue box added: Prior Skin Malignancies: All prior skin malignancies that have been treated should be reported as a Prior malignancy comorbidity; however, only melanoma will be given an HCT-CI score. If an Other skin malignancy (basal cell, squamous) is selected, an HCT-CI score is not given. |
12/20/2023 | Appendix J: Reporting Comorbidities | Add | Clarification added for mild hepatic criteria: Hepatic, mild: Any one or more of the following:
|
10/5/2023 | Appendix J: Reporting Comorbidities | Add | Further clarification added for pediatric invasive fungal infections: Infection: Pediatrics: The presence of one or more of the following: - History of invasive fungal infection (refer to Is there a history of invasive fungal infection? manual instructions located under the 2400 Comorbid Conditions section for further clarification) - Infection requiring antimicrobial treatment continued after Day 0 Do not report an infection comorbidity if the infection resolved prior to infusion and there was a recommendation to continue, or the recipient continued medication post-infusion as prophylaxis |
10/5/2023 | Appendix J: Reporting Comorbidities | Add | Further clarification added for pediatric mechanical ventilation: Pulmonary, severe: Pediatrics: Any one or more of the following at the time of pre-infusion evaluation: - Adjusted DLCO ≤ 65% - FEV1 ≤ 65%** - Dyspnea at rest attributed to pulmonary disease and not anemia - Requires intermediate or continuous supplemental oxygen - History of mechanical ventilation (refer to Is there a history of mechanical ventilation? manual instructions located under the 2400 Comorbid Conditions section for further clarification) Do not report if intubated due to premature birth for <24 hours. |
8/28/2023 | Appendix J: Reporting Comorbidities | Add | Version 4 of Appendix J added. This version is an overhaul of the appendix for easier comorbidity reporting |
Need more help with this?
Don’t hesitate to contact us here.